908 Devices Inc.

908 Devices Inc.

MASSNYSE / NASDAQHealthcareSmall cap

$8.67-$0.70 (-7.5%)

Last close · Data as of Nov 20, 2026

Market cap
$333.5M
P/E
17.1x
EV / EBITDA
-12.6x
Revenue
$56.2M
Net margin
34.7%
ROCE
-16.5%

+52.1% over the last year

908 Devices Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-24.7%
3M
-16.2%
6M
+24.2%
1Y
+52.1%
5Y
-66.5%

52-week range

Day change -$0.70 (-7.5%) from $9.37 to $8.67 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MASS, bought on each weekday since 2021.

News & filings

What 908 Devices filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was -23.7 million US dollars in fiscal 2025, a year of net profit.

Strengths (1)

  • Return on equity rose from -63.0% to 13.6% between fiscal 2024 and fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications.

Read moreShow less

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

Sector
Healthcare
Shares outstanding
36.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$333.5M
P/E
17.1x
P/B
2.3x
EV / EBITDA
-12.6x
EV / Sales
4.8x
P/S
5.9x
52-week high
$12.87
52-week low
$5.09

Profitability

Operating margin
-45.7%
Net margin
34.7%
EBITDA margin
-37.8%
ROE
13.6%
ROCE
-16.5%
ROIC
-26.1%
ROA
10.3%
Asset turnover
0.30

Growth

Revenue
$56.2M
Revenue growth, 1Y
17.7%
Revenue CAGR, 3Y
6.2%
Net profit growth, 1Y
-127.0%
Free cash flow
-$24.6M

Solvency

Current ratio
4.24
Debt / Equity
0.03
Debt / Assets
0.02
CFO / Net profit
-1.22
Cash / Market cap
21.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$56.2M
Cost of revenue$27.8M
Gross profit$28.4M
Operating expenses$54.1M
Research and development$15.6M
Selling, general and administrative$38.5M
Operating income-$25.7M
Interest and other-$7.7M
Pretax income-$33.3M
Tax and other-$52.8M
Net income$19.5M

Revenue and net profit

Revenue grew 17.7% in FY2025; net profit is the dashed line.

908 Devices Inc. revenue and net profit by fiscal year
908 Devices Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$46.9M-$33.6M
FY2023$50.2M-$36.4M
FY2024$47.7M-$72.2M
FY2025$56.2M$19.5M

Cash flows

FY2025: -$23.7M from operations, -$24.6M free after investment (dashed).

908 Devices Inc. operating and free cash flow by fiscal year
908 Devices Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$20.9M-$23.0M
FY2023-$25.1M-$27.1M
FY2024-$30.2M-$30.8M
FY2025-$23.7M-$24.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$56.2M+17.7%1Y
EBITDA
-$21.2M
Net profit
$19.5M
Cash from operations
-$23.7M
Free cash flow
-$24.6M
Revenue CAGR, 3Y
6.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$56.2M-$21.2M$19.5M-$24.6M13.6%+17.7%-127.0%

Monthly returns

Month-by-month returns of MASS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$190.1M
Liabilities$46.4M
Equity$143.7M
Paid-in capital$366.9M
Retained earnings-$223.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MASS highlighted.

P/E against peers

MASS trades at 17.1x earnings against a peer median of -4.2x.

  1. 908 Devices Inc. (this company)17.1x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
908 Devices Inc.MASSthis company$333.5M17.1x2.3x13.6%-12.6x
Greenwich LifeSciences, Inc.GLSI$347.1M-22.0x137.0x-623.1%—
Larimar Therapeutics, Inc.LRMR$341.8M—4.4x-212.2%—
Enanta Pharmaceuticals, Inc.ENTA$341.1M-4.2x5.3x-126.5%-5.1x
Verastem, Inc.VSTM$339.2M-1.6x5.9x-366.2%-1.1x
Simulations Plus, Inc.SLP$336.4M-5.2x2.7x-51.9%20.8x
Abeona Therapeutics Inc.ABEO$331.7M4.7x2.1x44.7%3.5x
Humacyte, Inc.HUMA$330.8M-8.1x106.4x-1313.4%-15.5x
Organogenesis Holdings Inc.ORGO$319.1M8.6x1.1x12.3%3.7x
Peer median—-4.2x4.8x-169.4%1.2x

Year-to-date ROI

MASS since 1 January, against earlier years.

Historical volatility

MASS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

908 Devices Inc. operating margin by fiscal year
908 Devices Inc. operating margin by fiscal year
DateOperating margin
FY2022-75.5%
FY2023-84.9%
FY2024-62.7%
FY2025-45.7%
LineFY2025
Cost of revenueCost Of Revenue$27.8M
Gross profitGross Profit$28.4M
Operating expensesOperating Expense$54.1M
Research and developmentResearch And Development$15.6M
Selling, general and administrativeSelling General And Administration$38.5M
Total expensesTotal Expenses$81.9M
Pretax incomePretax Income-$33.3M

Learn while you research

Academy chapters picked for 908 Devices Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →